Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25918022 | 0.94 | KDM4E (0.30) | ALDH1A1KDM4E | |
| SCHEMBL30723993 | 0.94 | KDM4E (0.30) | ALDH1A1KDM4E | |
| SCHEMBL25917446 | 0.91 | RXRA (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL25917544 | 0.85 | CYP4F2 (0.42) | ALDH1A1L3MBTL1GAACYP4F2CYP4A11 | |
| SCHEMBL24179526 | 0.84 | RXRA (0.31) | — | |
| SCHEMBL30723887 | 0.84 | RXRA (0.31) | — | |
| SCHEMBL25917491 | 0.83 | RXRA (0.37) | ALDH1A1ELANEEPHX2CYP4F2CYP4A11 | |
| SCHEMBL24179494 | 0.79 | RXRA (0.37) | CYP4F2CYP4A11KDM4E | |
| SCHEMBL30724046 | 0.78 | RXRA (0.35) | ALDH1A1ELANECYP4F2CYP4A11MEN1 | |
| SCHEMBL25918141 | 0.78 | RXRA (0.35) | ALDH1A1ELANECYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | SLC5A11, CYP11B2, CYP4F11 | ALDH1A1 1288/4885ELANE 3676/4885EPHX2 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.